Biotech

Startups

Biotech Startups Essentials publishes only the best Biotech news and links, carefully hand-picked and curated by top biotech experts.

Top news of the week: 05.10.2023.

NASDAQ
Initial public offering
Disease
Biotechnology
Science
Government

@Genetic Engineering & Biotechnology News shared
On Oct 4, 2023
Fake tweet - https://www.investing.com/news/stock-market-news/biotech-ipos-see-gradual-resurgence-in-q3-2023-investor-caution-persists-93CH-3189378
Open
Biotech IPOs see gradual resurgence in Q3 2023, investor caution persists

Biotech IPOs see gradual resurgence in Q3 2023, investor caution persists

Biotech IPOs see gradual resurgence in Q3 2023, investor caution persists

@Genetic Engineering & Biotechnology News shared
On Oct 4, 2023
Fake tweet - https://wealthofgeeks.com/lexeos-100-million-ipo-jab-in-the-arm-for-biotech/
Open
Lexeo’s $100 Million IPO: Jab in the Arm for Biotech?

Lexeo’s $100 Million IPO: Jab in the Arm for Biotech?

October 3, 2023 It's been nothing but crickets in the biotech initial public offering (IPO) space this year, but investors who are hungry for a new pharma

@Genetic Engineering & Biotechnology News shared
On Sep 30, 2023
Fake tweet - https://tokenist.com/blockbuster-listings-in-sep-spark-new-life-into-ipo-etfs/?utm_source=rss&utm_me
Open
Blockbuster Listings in Sep. Spark New Life into IPO ETFs

Blockbuster Listings in Sep. Spark New Life into IPO ETFs

After hike-induced hibernation, IPO awakening signs emerge but where to get maximum IPO exposure?

@Genetic Engineering & Biotechnology News shared
On Oct 4, 2023
Fake tweet - https://journals.plos.org/plospathogens/article?id=10.1371/journal.ppat.1011662
Open
VP2 residue N142 of coxsackievirus A10 is critical for the interaction with KREMEN1 receptor and neutralizing antibodies and the pathogenicity in mice

VP2 residue N142 of coxsackievirus A10 is critical for the interaction with KREMEN1 receptor and neutralizing antibodies and the pathogenicity in mice

Author summary Coxsackievirus A10 (CVA10) is an emerging pathogen that causes hand, foot, and mouth disease. No approved vaccines or antiviral treatments for CVA10 infection are yet ...

@Genetic Engineering & Biotechnology News shared
On Sep 29, 2023
Fake tweet - https://blogs.timesofisrael.com/israels-fate-hangs-in-the-balance-yom-kippur-5784/
Open
Israel’s Fate Hangs in the Balance – Yom Kippur 5784

Israel’s Fate Hangs in the Balance – Yom Kippur 5784

From the blog of David Lerner at The Times of Israel

@Genetic Engineering & Biotechnology News shared
On Oct 3, 2023
Fake tweet - https://indianexpress.com/article/cities/pune/indian-scientists-welcome-nobel-prize-for-medicine-say-mrna-vaccines-can-be-developed-for-tb-dengue-other-diseases-8965746/
Open
Indian scientists welcome Nobel Prize for medicine, say mRNA vaccines can be developed for TB, dengue, other diseases

Indian scientists welcome Nobel Prize for medicine, say mRNA vaccines can be developed for TB, dengue, other diseases

Dr Vinod Paul, member, the National Institution for Transforming India (NITI Aayog),said the mRNA pathway for vaccines has opened new doors.

@Genetic Engineering & Biotechnology News shared
On Sep 30, 2023
Fake tweet - https://www.globalresearch.ca/vaccines-grown-lettuce-rep-massie-asks-house-bar-fda-usda-funding-transgenic-edible-vaccines/5834385
Open
Vaccines Grown in Lettuce? Rep. Massie Asks House to Bar FDA, USDA From Funding Transgenic Edible Vaccines

Vaccines Grown in Lettuce? Rep. Massie Asks House to Bar FDA, USDA From Funding Transgenic Edible Vaccines

All Global Research articles can be read in 51 languages by activating the Translate Website button below the author’s name. To receive Global Research’s Daily Newsletter (selected ...

@Genetic Engineering & Biotechnology News shared
On Sep 30, 2023
Fake tweet - https://www.thehindubusinessline.com/markets/main-board-ipos-make-quiet-waves-in-fundraising-frenzy/article67362295.ece
Open
Healthy changes are happening in the primary market quietly

Healthy changes are happening in the primary market quietly

India Inc raised ₹17,500-cr in Q2, 65% of 2023 total. 24 companies from diverse sectors tapped capital markets. Funds raised ranged from ₹2,800-cr to ₹71-cr. 65-70% of funds were fresh ...